debrisoquin has been researched along with quinidine in 38 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 12 (31.58) | 18.7374 |
1990's | 16 (42.11) | 18.2507 |
2000's | 9 (23.68) | 29.6817 |
2010's | 1 (2.63) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Commandeur, JN; Funae, Y; Hiroi, T; ter Laak, AM; Venhorst, J; Vermeulen, NP | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Araki, J; Masubuchi, Y; Narimatsu, S; Suzuki, T | 1 |
Bélanger, PM; Eichelbaum, M; Fiset, C; Giguère, R; Gilbert, M; Grech-Bélanger, O; Kroemer, HK; Moerike, K; Rouleau, JR; Turgeon, J | 1 |
Ayesh, R; Cholerton, S; Dawling, S; Hayler, A; Idle, JR; Oates, NS; Smith, RL; Widdop, B | 1 |
Broly, F; Caron, J; Lhermitte, M; Libersa, C; Vandamme, N | 1 |
Brøsen, K; Gram, LF; Kragh-Sørensen, P | 1 |
Brøsen, K; Meyer, UA; Zeugin, T | 1 |
Anthony, LB; Roden, DM; Wood, AJ; Zhou, HH | 1 |
Gonzalez, FJ; Hardwick, JP; Inaba, T; Kalow, W; Tyndale, RF | 1 |
Funck-Brentano, C; Roden, DM; Turgeon, J; Woosley, RL | 1 |
Agron, L; Bigot, MC; Camsonne, R; Dao, MT; Debruyne, D; Gram, LF; Grollier, G; Lacotte, J; Moulin, M | 1 |
Dahlqvist, R; Dumont, E; Spina, E; Steiner, E | 1 |
Boobis, AR; Davies, DS; Kobayashi, S; Murray, S; Sesardic, D; Watson, D | 1 |
Hawes, EM; Inaba, T; McKay, G; Midha, KK; Muralidharan, G | 1 |
Crewe, HK; Lennard, MS; Otton, SV; Tucker, GT; Woods, HF | 1 |
Boobis, AR; Davies, DS; Murray, S; Seddon, CE; Speirs, CJ | 1 |
Bertilsson, L; Brøsen, K; Gram, LF; Haghfelt, T | 1 |
Dayer, P; Eichelbaum, M; Kronbach, T; Meyer, UA | 1 |
Dayer, P; Leemann, T; Meyer, UA | 1 |
Inaba, T; Mahon, WA; Tyndale, RE | 1 |
Almeyda, J; Levantine, A | 1 |
Huang, Y; Masubuchi, Y; Mizukami, T; Narimatsu, S; Suzuki, T | 2 |
Bertilsson, L; Dahl, ML; Eichelbaum, M; Ingelman-Sundberg, M; Johansson, I; Meese, CO; Säwe, J; Yue, QY | 1 |
Dayer, P; Devi, KP; Leemann, TD | 1 |
Ebner, T; Eichelbaum, M | 1 |
Cooper, JK; Hawes, EM; Korchinski, ED; Midha, KK; Muralidharan, G | 1 |
Caraco, Y; Sheller, J; Wood, AJ | 2 |
Blackburn, MG; Ellis, SW; Harlow, J; Hayhurst, GP; Larsson, C; Lennard, MS; Lightfoot, T; Lim, CK; Mahling, J; Rowland-Yeo, K; Smith, G; Tucker, GT; Wolf, CR | 1 |
Andersson, K; Bertilsson, L; Dahl, M; Dalén, P | 1 |
Chiba, M; Lin, JH; Lin, Y; Neway, W; Nishime, JA | 1 |
Adedoyin, A; Branch, RA; Frye, RF; Romkes, M; Wilson, JW | 1 |
Gelboin, HV; Gonzalez, FJ; Granvil, CP; Idle, JR; Krausz, KW | 1 |
Katoh, M; Nakajima, M; Sawada, T; Soeno, Y; Tateno, C; Yokoi, T; Yoshizato, K | 1 |
Guo, B; He, MM; Li, C; Liu, H; Shen, H; Wang, L; Wrighton, SA | 1 |
2 review(s) available for debrisoquin and quinidine
Article | Year |
---|---|
Inhibition of desipramine 2-hydroxylation by quinidine and quinine in rapid and slow debrisoquine hydroxylators.
Topics: Debrisoquin; Depression, Chemical; Desipramine; Humans; Hydroxylation; Isoquinolines; Phenotype; Quinidine; Quinine | 1989 |
Cutaneous reactions to cardiovascular drugs.
Topics: Adrenergic beta-Antagonists; Cardiovascular Diseases; Clonidine; Debrisoquin; Digitalis Glycosides; Drug Eruptions; Ethacrynic Acid; Furosemide; Guanethidine; Humans; Hydralazine; Mercury; Methyldopa; Nitroglycerin; Pentaerythritol Tetranitrate; Procainamide; Quinidine; Thiazines | 1973 |
5 trial(s) available for debrisoquin and quinidine
Article | Year |
---|---|
Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism.
Topics: Adult; Anilides; Biological Availability; Debrisoquin; Drug Interactions; Electrocardiography; Encainide; Humans; Male; Metabolic Clearance Rate; Middle Aged; Polymorphism, Genetic; Quinidine | 1989 |
Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Chromatography, High Pressure Liquid; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Debrisoquin; Depression, Chemical; Enzyme Inhibitors; Humans; Hydroxylation; Male; Mixed Function Oxygenases; Oxidation-Reduction; Phenotype; Polymorphism, Genetic; Quinidine | 1996 |
Pharmacogenetic determination of the effects of codeine and prediction of drug interactions.
Topics: Adult; Codeine; Cross-Over Studies; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Double-Blind Method; Drug Interactions; Humans; Male; Pupil; Quinidine; Reflex, Pupillary; Respiration | 1996 |
Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects.
Topics: Adult; Analgesics, Opioid; Asian People; Biotransformation; Codeine; Cross-Over Studies; Dealkylation; Debrisoquin; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Female; Humans; Male; Morphine; Psychomotor Performance; Pupil; Quinidine; Respiratory Mechanics; White People | 1999 |
Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.
Topics: Administration, Oral; Adult; Alleles; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gene Dosage; Genotype; Humans; Hydroxylation; Male; Quinidine | 2000 |
31 other study(ies) available for debrisoquin and quinidine
Article | Year |
---|---|
Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities.
Topics: Alcohol Oxidoreductases; Amino Acid Sequence; Animals; Aryl Hydrocarbon Hydroxylases; Binding Sites; Coumarins; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 2; Enzyme Inhibitors; Humans; Isoenzymes; Kinetics; Ligands; Mixed Function Oxygenases; Models, Molecular; Molecular Sequence Data; Protein Binding; Quinidine; Quinine; Rabbits; Rats; Sequence Homology, Amino Acid; Sparteine; Species Specificity | 2003 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Metabolic activation of lidocaine and covalent binding to rat liver microsomal protein.
Topics: Animals; Biotransformation; Carbon Monoxide; Cysteine; Cytochrome P-450 Enzyme System; Debrisoquin; Dose-Response Relationship, Drug; Female; Glutathione; Lidocaine; Male; Microsomes, Liver; NADP; Oxygen; Proadifen; Propranolol; Proteins; Quinidine; Rats; Rats, Inbred Strains | 1992 |
Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man.
Topics: Administration, Oral; Adult; Debrisoquin; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Phenotype; Polymorphism, Genetic; Quinidine | 1991 |
Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers.
Topics: Adult; Debrisoquin; Desipramine; Female; Humans; Male; Metabolic Clearance Rate; Molecular Structure; Nortriptyline; Phenotype; Quinidine; Quinine; Reference Values; Stereoisomerism | 1991 |
Single-dose quinidine treatment inhibits mexiletine oxidation in extensive metabolizers of debrisoquine.
Topics: Debrisoquin; Drug Antagonism; Humans; Metabolic Clearance Rate; Mexiletine; Oxidation-Reduction; Quinidine | 1991 |
Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin.
Topics: Administration, Oral; Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Chromatography, Thin Layer; Debrisoquin; Desipramine; Drug Interactions; Humans; Imipramine; Male; Mephenytoin; Phenotype; Quinidine; Sparteine | 1991 |
Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine.
Topics: Antibodies; Cells, Cultured; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; DNA; Humans; Imipramine; Isoenzymes; Kidney; Kinetics; Methotrimeprazine; Microsomes, Liver; Mixed Function Oxygenases; Oxidation-Reduction; Polymorphism, Genetic; Quinidine; Sparteine; Transfection | 1991 |
Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation.
Topics: Adult; Analysis of Variance; Debrisoquin; Drug Interactions; Electrocardiography; Humans; Hydroxylation; Male; Metabolic Clearance Rate; Propranolol; Quinidine; Stereoisomerism | 1990 |
Sparteine metabolism capacity in human liver: structural variants of human P450IID6 as assessed by immunochemistry.
Topics: Animals; Blotting, Western; Cytochrome P-450 Enzyme System; Debrisoquin; Ethanolamines; Humans; Immunochemistry; In Vitro Techniques; Kinetics; Liver; Quinidine; Rats; Rats, Inbred Strains; Sparteine | 1990 |
Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis.
Topics: Adult; Aged; Alcoholism; Antipyrine; Chromatography, Liquid; Debrisoquin; Female; Half-Life; Humans; Isoquinolines; Liver Cirrhosis, Alcoholic; Male; Middle Aged; Quinidine | 1989 |
The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man.
Topics: Animals; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Debrisoquin; Humans; In Vitro Techniques; Liver; Male; Mixed Function Oxygenases; Quinidine; Quinine; Rats; Rats, Inbred Strains; Species Specificity | 1989 |
Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism.
Topics: Amphetamines; Animals; Debrisoquin; Female; Humans; Isoquinolines; Methamphetamine; Polymorphism, Genetic; Quinidine; Rats; Rats, Inbred Lew; Rats, Inbred Strains | 1989 |
Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.
Topics: Cytochrome P-450 Enzyme System; Dealkylation; Debrisoquin; Humans; Hydroxylation; In Vitro Techniques; Isoquinolines; Kinetics; Metoprolol; Microsomes, Liver; Quinidine; Quinine; Sparteine | 1988 |
Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
Topics: Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; Female; Humans; In Vitro Techniques; Isoenzymes; Isoquinolines; Male; Microsomes, Liver; Mixed Function Oxygenases; Oxidoreductases; Phenotype; Quinidine; Quinine | 1986 |
Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment.
Topics: Aged; Debrisoquin; Depression, Chemical; Humans; Hydroxylation; Isoquinolines; Male; Middle Aged; Phenotype; Quinidine | 1987 |
Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
Topics: Adult; Aged; Binding, Competitive; Cytochrome P-450 Enzyme System; Debrisoquin; Ethanolamines; Humans; Hydroxylation; Isoenzymes; Isoquinolines; Kinetics; Microsomes, Liver; Middle Aged; Phenotype; Polymorphism, Genetic; Quinidine; Sparteine | 1987 |
Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers.
Topics: Adult; Debrisoquin; Depression, Chemical; Humans; Metoprolol; Oxidation-Reduction; Quinidine; Stereoisomerism | 1986 |
Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.
Topics: Adult; Cytochrome P-450 Enzyme System; Debrisoquin; Female; Humans; Isoquinolines; Male; Middle Aged; Oxidation-Reduction; Quinidine; Sparteine | 1986 |
Development of a high-performance liquid chromatographic method for the analysis of enatiomer/enantiomer interaction in oxidative metabolism of bunitrolol in rat liver microsomes.
Topics: Adrenergic beta-Antagonists; Animals; Chromatography, High Pressure Liquid; Debrisoquin; Gas Chromatography-Mass Spectrometry; Male; Microsomes, Liver; Oxidation-Reduction; Propanolamines; Quinidine; Quinine; Rats; Rats, Wistar; Stereoisomerism | 1994 |
Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
Topics: Asian People; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Debrisoquin; Genotype; Haplotypes; Humans; Hydroxylation; Metabolic Clearance Rate; Mixed Function Oxygenases; Polymorphism, Restriction Fragment Length; Quinidine; Stereoisomerism; White People | 1993 |
Similar effect of oxidation deficiency (debrisoquine polymorphism) and quinidine on the apparent volume of distribution of (+/-)-metoprolol.
Topics: Adult; Blood Proteins; Debrisoquin; Drug Interactions; Humans; Male; Metoprolol; Phenotype; Polymorphism, Genetic; Protein Binding; Quinidine | 1993 |
The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.
Topics: Aprindine; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; Humans; Hydroxylation; Kinetics; Microsomes, Liver; Mixed Function Oxygenases; Polymorphism, Genetic; Propafenone; Quinidine; Sparteine | 1993 |
In-vitro metabolic interaction of bunitrolol enantiomers in rabbit liver microsomes.
Topics: Adrenergic beta-Antagonists; Animals; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Debrisoquin; Female; Hydroxylation; In Vitro Techniques; Kinetics; Male; Microsomes, Liver; Propanolamines; Quinidine; Quinine; Rabbits; Rats; Rats, Wistar; Species Specificity; Stereoisomerism | 1996 |
Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.
Topics: Alanine; Amino Acid Substitution; Aspartic Acid; Binding Sites; Catalytic Domain; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Enzyme Inhibitors; Kinetics; Ligands; Metoprolol; Mutagenesis, Site-Directed; Oxidation-Reduction; Propranolol; Quinidine; Quinine; Serine; Substrate Specificity; Yeasts | 2000 |
Comparative in vitro metabolism of indinavir in primates--a unique stereoselective hydroxylation in monkey.
Topics: Animals; Antibodies, Monoclonal; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Debrisoquin; HIV Protease Inhibitors; Humans; Hydroxylation; Indinavir; Kinetics; Microsomes, Liver; Mixed Function Oxygenases; Molecular Conformation; Molecular Structure; Primates; Quinidine; Quinine | 2000 |
In vivo modulation of CYP enzymes by quinidine and rifampin.
Topics: Acetylation; Administration, Oral; Adrenergic alpha-Antagonists; Adult; Anti-Arrhythmia Agents; Antibiotics, Antitubercular; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dapsone; Debrisoquin; Drug Administration Schedule; Enzyme Inhibitors; Humans; Male; Mephenytoin; Mixed Function Oxygenases; Quinidine; Reference Values; Rifampin; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Theophylline | 2000 |
4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine.
Topics: Adrenergic Agents; Antimalarials; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Hydroxylation; Microsomes; Quinidine; Quinine | 2002 |
In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver.
Topics: Adrenergic Agents; Animals; Chimera; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Drug Interactions; Humans; Infant; Liver; Male; Mice; Mice, SCID; Models, Animal; Paroxetine; Quinidine; Urokinase-Type Plasminogen Activator | 2007 |
Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.
Topics: Atomoxetine Hydrochloride; Cocaine; Codeine; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Dextromethorphan; Enzyme Inhibitors; Ethanolamines; Fluoxetine; Humans; Hydroxylation; Imipramine; Kinetics; Microsomes; Molecular Structure; Nortriptyline; Polymorphism, Single Nucleotide; Propylamines; Quinidine; Recombinant Proteins; Thioridazine; Tramadol | 2007 |